-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Approximately 25% of non-small cell lung cancer ( NSCLC ) are diagnosed as stage III patients, most of which are unresectable
Approximately 25% of non-small cell lung cancer ( NSCLC ) are diagnosed as stage III patients, most of which are unresectable
KEYNOTE-799 is a non-random, open-label Phase II study conducted in 52 research centers in 10 countries
KEYNOTE-799 is a non-random, open-label Phase II study conducted in 52 research centers in 10 countries
research summary
The ORR of cohort A patients was 70.
The ORR of cohort A patients was 70.
Two-queue ORR
The duration of remission (DOR) of the two cohorts was not reached
The duration of remission (DOR) of the two cohorts was not reached
Duration of Response (DOR) for the two cohorts
Treatment-related adverse events (AE), the incidence of cohort A and B were 93.
Treatment-related adverse events (AE), the incidence of cohort A and B were 93.
Adverse events of treatment in two cohorts
In summary, Pembrolizumab combined with concurrent chemotherapy and radiotherapy (cCRT) is a feasible strategy for the treatment of unresectable stage III NSCLC with controllable toxicity
In summary, Pembrolizumab combined with concurrent chemotherapy and radiotherapy (cCRT) is a feasible strategy for the treatment of unresectable stage III NSCLC with controllable toxicity
Original source:
Salma K Jabbour, Ki Hyeong Lee, Nikolaj Frost, et al.
Pembrolizumab Plus Concurrent Chemoradiation Therapy in Patients With Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer: The Phase 2 KEYNOTE-799 Nonrandomized Trial.
JAMA Oncol.
2021 Jun 4.
doi: 10.
1001/jamaoncol.
2021.
2301.
Online ahead of print.
Pembrolizumab Plus Concurrent Chemoradiation Therapy in Patients With Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer: The Phase 2 KEYNOTE-799 Nonrandomized Trial.
JAMA Oncol.
2021 Jun 4.
doi: 10.
1001/jamaoncol.
2021.
2301.
Online ahead of print.
Leave a message here
